Compounds and methods for diagnosis and treatment of viral infections
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for diagnosing and/or treating flaviviridae-family viruses including Zika virus, dengue virus, and yellow fever.
1. A method of treating a disease comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
wherein each X is independently H, L 1 -A, or L 2 -R; each L 1 and L 2 are independently linkers; each A independently comprises a therapeutic agent or a detection label or H; each R independently comprises a CD206 targeting moiety or H; and n is an integer greater than zero; and wherein at least one R is a CD206 targeting moiety and at least one A is a chemotherapeutic agent wherein the disease is selected from Zika Virus, Yellow Fever, and Dengue Fever.
2. The method of claim 1 , wherein a linker is used to attach the one or more CD206 targeting moieties and/or one or more chemotherapeutic agent.
3. The method of claim 1 , wherein at least one L 1 comprises a degradable linker.
4. The method of claim 1 , wherein at least one L 1 comprises a hydrolysable linker.
5. The method of claim 1 , wherein at least one L 1 comprises an acid-sensitive linker.
6. The method of claim 1 , wherein treatment is effective through binding of the compound to the CD206 expressing cells of the subject and not through binding to the virus.
7. The method of claim 1 , wherein administration of the compound treats the disease and decreases disease causing virus through binding of the subject's CD206 expressing cells.
8. The method of claim 1 , wherein the chemotherapeutic agent is doxorubicin or dexamethasone.
9. A method of targeting zika virus by targeting macrophages comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
wherein each X is independently H, L 1 -A, or L 2 -R; each L 1 and L 2 are independently linkers; each A independently comprises a therapeutic agent or a detection label or H; each R independently comprises a CD206 targeting moiety or H; and n is an integer greater than zero; and wherein at least one R is a CD206 targeting moiety and at least one A is a chemotherapeutic agent to treat the disease and decrease the amount of disease causing virus.
10. The method of claim 9 , wherein administration of the compound treats the disease and decreases disease causing virus through binding of the subject's CD206 expressing cells.
11. The method of claim 9 , wherein the chemotherapeutic agent is doxorubicin or dexamethasone.
12. A method of treating a disease caused by infection by a flaviviridae family virus comprising administering to a subject in need thereof an effective amount of a compound of Formula (II):
wherein each X is independently H, L 1 -A, or L 2 -R; each L 1 and L 2 are independently linkers; each A independently comprises a therapeutic agent or a detection label or H; each R independently comprises a CD206 targeting moiety or H; and n is an integer greater than zero; and wherein at least one R is a CD206 targeting moiety and at least one A is doxorubicin or dexamethasone.